8-K
filed March 26, 2024, 7:59 PM ET
ticker REPL
CIK 0001737953
leadership
confidence high
sentiment neutral
materiality 0.75
Replimune names Sushil Patel CEO effective April 1; Astley-Sparke becomes Executive Chairman
Replimune Group, Inc.
- Dr. Sushil Patel appointed CEO effective April 1, 2024; previously Chief Strategy Officer.
- Philip Astley-Sparke transitions from CEO to Executive Chairman; Dieter Weinand becomes Lead Independent Director.
- Robert Coffin moves to Founder & Chief Scientist advisory role; Paul Bullock promoted to Chief Manufacturing Officer.
- Colin Love (COO) retiring May 31; Pamela Esposito and Tanya Lewis leave executive roles but remain advisors.
- Company on track to submit RP1 BLA in 2H 2024 for anti-PD1 failed melanoma.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Paul Bullock changed role as chief manufacturing officer at Replimune Group, Inc..
- Action
- promoted
- Role
- chief manufacturing officer
Exact text from the filing
Paul Bullock, the Company’s current senior vice president, operations and Framingham site head, is being promoted to the Company’s chief manufacturing officer effective April 1, 2024
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dr. Sushil Patel was appointed as chief executive officer at Replimune Group, Inc..
- Action
- appointed
- Role
- chief executive officer
Exact text from the filing
Dr. Sushil Patel, the Company’s current chief strategy officer, has been appointed as the Company’s chief executive officer, effective as of April 1, 2024
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dieter Weinand changed role as lead independent director of the Board at Replimune Group, Inc..
- Action
- transitioned
- Role
- lead independent director of the Board
Exact text from the filing
Dieter Weinand, the Company’s current chair of the Board, will transition into the newly created role of the lead independent director of the Board
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Tanya Lewis changed role as advisor at Replimune Group, Inc..
- Action
- left executive position
- Role
- advisor
Exact text from the filing
Tanya Lewis, the Company’s current chief development operations officer, will leave their executive positions and plan to continue to lend their functional expertise in an advisory capacity
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Philip Astley-Sparke changed role as executive chairman of the Board at Replimune Group, Inc..
- Action
- transitioned
- Role
- executive chairman of the Board
Exact text from the filing
Philip Astley-Sparke, the Company’s current chief executive officer, will transition to the role of executive chairman of the Board
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Dr. Colin Love retired as chief operating officer at Replimune Group, Inc..
- Action
- retired
- Role
- chief operating officer
Exact text from the filing
Dr. Colin Love, the Company’s current chief operating officer, will retire from the Company, effective May 31, 2024
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.